AlphAIAlphAI — Financial news for AI agents
finance.biggo.comOCT 192 min read$MANE

Oral Hair-Loss Drug Aces Phase 3 Trial, Veradermics Shares Jump More Than 11% Intraday

Veradermics' (MANE) oral hair-loss drug VDPHL01 met all goals in a Phase 3 trial, showing significant hair growth. Shares rose over 11% intraday. The drug is an extended-release oral minoxidil formulation, aiming to improve convenience and adherence. Veradermics plans to seek regulatory approval, but direct comparisons with generic minoxidil are pending.

Original reporting
finance.biggo.com
Published Oct 19, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MANE
Bullish
high confidence
Mentioned
$MANE
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$MANEBullishHigh
01

Why it matters

The trial’s positive results represent a pivotal step toward FDA filing, potentially creating a first‑in‑class oral hair‑loss drug and unlocking a sizable cash‑pay market.

02

Market read

The announcement triggered an immediate >11% stock surge, indicating strong market interest and potential for further upside pending regulatory approval.

03

What to watch

Regulatory review timeline and payer reimbursement decisions could moderate upside.

Relevance 8/10Novelty 9/10Timing: intraday today

Background

Veradermics (MANE) is a U.S. biopharma focused on hair‑loss therapies. The Phase 3 trial tested an extended‑release oral minoxidil formulation.

Company-level read

Ticker impact

$MANEBullishHigh confidence
Context

Veradermics announced its Phase 3 trial met all goals, causing the stock to jump over 11% intraday.

Expected impact

upward pressure as investors price in potential FDA approval and market opportunity.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; the stock already reacted strongly.

Market effects

Sector

May boost the broader hair‑loss and dermatology biotech sector as investors reassess pipeline opportunities.

Regional

Limited to US‑listed biotech investors; no broader regional effect.

Global

Potentially relevant to global pharma investors tracking oral hair‑loss treatments.

Counterpoint

What could challenge this read

Skeptics may point to lack of head‑to‑head data versus generic minoxidil and pricing uncertainty.

Key entities

  • company
    Veradermics

    U.S. biopharmaceutical company developing oral hair‑loss drug VDPHL01.

  • executive
    Reid Waldman

    CEO of Veradermics who commented on the trial results.

Read at source← All news

StoryVeradermics reports Phase 3 trial meets all endpoints for oral hair‑loss pill

Also covered by

1 outlet

Related articles

OCT 19
MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.

finance.yahoo.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics Stock Rises 7% After Positive Phase 3 Hair Loss Trial Results

Veradermics (MANE) stock rose 6.98% to $116.42 after positive Phase 3 trial results for its hair loss treatment VDPHL01, meeting all endpoints with statistical significance. The trial involved 536 males with mild-to-moderate hair loss, showing significant hair count increases compared to placebo. The company expects further data later this year and in 2027.

rttnews.com2 min
OCT 19
$MANEHighAI 8/10

Veradermics posts positive Phase 3 '304' topline: VDPHL01 raises hair count up to 36.4 hairs/cm², no treatment‑related SAEs

Veradermics (MANE) reported positive Phase 3 results for VDPHL01, showing significant hair growth and a favorable safety profile. The study met all endpoints, with hair count increases of 28.6 (QD) and 36.4 (BID) hairs/cm² vs. 6.6 for placebo. Patient-reported improvements were 78.8% (QD) and 85.0% (BID) vs. 35.3% for placebo. No treatment-related serious adverse events were reported.

tradingview.com1 min